+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Therapy Trends: Rheumatoid Arthritis -- KOL Insight and Consensus Outlook Modules

  • ID: 2584084
  • Report
  • June 2013
  • Region: Global
  • 133 Pages
  • FirstWord Publishing
What the future holds

Over the next few years, the global Rheumatoid Arthritis (RA) market is expected to grow from $18.6 billion in 2012 to $26.0 billion in 2017. The continued uptake of anti-TNFs, expanded use of other biologics, and the introduction of Pfizer's US approved oral therapy Xeljanz (tofacitinib) will drive sales in this lucrative indication. So what are the key factors impacting the current and future changes? And is there room for your product in this crowded arena?

The next five years:

Gain instant access to an accurate, unbiased, qualitative review of the latest treatment trends, and five-year quantitative RA market forecast with FirstWord's Therapy Trends: Rheumatoid Arthritis. This comprehensive FirstWord research is available to you in two modules: KOL Insight and Consensus Outlook.

In addition, both Therapy Trends modules provide you with ‘live' updates on the potential impact of the latest key market RA events over the next 12 months. You'll receive these directly, within days of each event's occurrence.

- KOL Insight: Rheumatoid Arthritis module is compiled from exclusive interviews with 12 leading Rheumatoid Arthritis KOLs from the US and Europe

- Consensus Outlook: Rheumatoid Arthritis module presents you with a data analysis module, annual historical and forecast product-level sales data from an average of leading equity analysts' projections

Your Critical Questions Answered:

- Which key factors are driving RA drugs up the treatment algorithm?
- What will be the positioning and impact of Xeljanz on the market?
- What does the Phase III OSKIRA results mean for Rigelâs fostamatinib?
- How are biologics (Orencia, Rituxan, Actemra) affecting the market?
- Could new anti-TNFs (Cimzia, Simponi) threaten first-line Humira?
- How do late-stage pipeline products compare with existing brands?
- What are the unmet clinical needs for RA physicians and patients?
- What strategies are companies using to position new RA agents?
- What are the strengths and flaws of oral, IV and SC arthritis agents?
- How could biosimilars erode current anti-TNF market shares?
- What are the market share forecasts by class and company?
- What will be the key future events that will impact future sales revenue?
- What and when will be the positive and negative events that will impact the market?
- How will future dynamics in the RA armamentarium unfold compared to historical trends?
Note: Product cover images may vary from those shown
Executive Summary



Current Rheumatoid Arthritis Marketplace

- Current treatment landscape

- Rheumatoid Arthritis market definition

- Current market overview

- Reimbursement of key Rheumatoid Arthritis brands

- UK advisory board's U-turn for wider use of RA drugs

- Unmet needs in Rheumatoid Arthritis

- Unmet need 1: More efficacious therapies

- Unmet need 2: Personalised medicine

- Unmet need 3: Earlier diagnosis for treatment

- Unmet need 4: Cheaper therapies

- Unmet need 5: Improved safety profile

- Unmet need 6: Drugs to halt or reverse damage

- Unmet need 7: Improved mode of administration

Current Rheumatoid Arthritis therapies

- Pivotal trial data of approved therapies

- Anti-TNF therapies

- Enbrel (etanercept; Amgen/Pfizer/Takeda) treatment trends

- Humira (adalimumab; Abbott/Eisai) treatment trends

- Remicade (infliximab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) treatment trends

- Simponi (golimumab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) treatment trends

- Cimzia (certolizumab; UCB) treatment trends

- Other biologic therapies

- Orencia (abatacept) treatment trends

- Rituxan/MabThera (rituximab; Genentech/Biogen Idec/Roche/ Chugai) treatment trends

- Actemra/RoActemra (tocilizumab; Chugai/Roche) treatment trends

- Current treatment algorithm

- Methotrexate: the first-line therapy of choice

- Anti-TNFs: second-line RA therapies

- The commercial challenge of RA drug switching

- Beyond TNF-inhibitors: second and third-line therapies

Future Rheumatoid Arthritis therapies

- Future treatment landscape

- Tofacitinib (CP-690,550; Pfizer/Takeda) treatment trends

- Fostamatinib disodium (R788; AstraZeneca/Rigel Pharmaceuticals) treatment trends

- Secukinumab (AIN457; Novartis) treatment trends

- More aggressive, earlier treatment

- Tofacitinib: expanded use as experience rises

- Numerous treatment options may confuse prescribers and patients

Future developments in Rheumatoid Arthritis

- Novel targets in the treatment of rheumatoid arthritis

- Biosimilar threat is imminent

- Eventual development of biomarkers will aid treatment

- Patient recruitment will be harder for developers

- Clinical trials will have to evolve in the future

FirstWord Rheumatoid Arthritis news analysis

- Positive Rheumatoid Arthritis key news events

- Current therapies

- Pipeline therapies

- Company therapies

- Negative Rheumatoid Arthritis key news events

- Marketed therapies

- Pipeline therapies

- Company therapies

Appendix 1

- KOL biographies

- KOLs from North America

- KOLs from Europe

Appendix 2

- Links to Rheumatoid Arthritis News Stories Jan 2011-May 2012
Note: Product cover images may vary from those shown